Galligan J J, Hess M C, Miller S B, Fink G D
Department of Pharmacology and Toxicology and the Neuroscience Program, Michigan State University, East Lansing, Michigan 48824, USA.
J Pharmacol Exp Ther. 2001 Feb;296(2):478-85.
ATP acts at P2 receptors to contract blood vessels and reactivity to vasoconstrictor agents is often altered in hypertension. This study was designed to identify P2 receptors in mesenteric arteries and veins and to determine whether ATP reactivity is altered in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Computer-assisted video microscopy was used to measure vessel diameter in vitro. ATP was a more potent constrictor of veins (EC(50) = 2.7 microM) than arteries (EC(50) = 196 microM) from normotensive rats; there was no change in ATP reactivity in vessels from DOCA-salt rats. The P2X1 receptor agonist alpha,beta-methylene ATP (alpha,beta-MeATP, 0.03-3 microM) contracted arteries but not veins. ATP-induced contractions in arteries were blocked by alpha,beta-MeATP (3 microM) desensitization. 2-Methylthio-ATP (0.1-10 microM), an agonist that can act at P2Y1 receptors, did not contract arteries or veins, whereas UTP, an agonist at rat P2Y2/P2Y4 receptors, contracted veins (EC(50) = 15 microM) and arteries (EC(50) = 24 microM). UTP-induced contractions of veins cross-desensitized with ATP, whereas UTP-induced contractions in arteries were unaffected by alpha,beta-MeATP-desensitization. The P2X/P2Y1 receptor antagonist pyridoxal-phosphate-6-azophenyl-2',4-disulfonic acid blocked ATP-induced contractions of arteries (IC(50) = 4.8 microM) but not veins. Suramin, an antagonist that blocks P2Y2 receptors, partly inhibited ATP- and UTP-induced contractions of veins. Immunohistochemical studies revealed P2X1 receptor immunoreactivity in arteries but not veins. These data indicate that mesenteric vascular reactivity to ATP is not altered in DOCA-salt hypertension. ATP acts at P2X1 and P2Y2 receptors to contract mesenteric arteries and veins, respectively, whereas in arteries UTP acts at an unidentified P2 receptor.
ATP作用于P2受体使血管收缩,在高血压状态下对血管收缩剂的反应性常发生改变。本研究旨在鉴定肠系膜动脉和静脉中的P2受体,并确定醋酸脱氧皮质酮(DOCA)-盐高血压大鼠中ATP反应性是否改变。采用计算机辅助视频显微镜体外测量血管直径。ATP对正常血压大鼠静脉的收缩作用更强(半数有效浓度[EC(50)] = 2.7微摩尔),而对动脉的收缩作用较弱(EC(50) = 196微摩尔);DOCA-盐大鼠血管中ATP反应性无变化。P2X1受体激动剂α,β-亚甲基ATP(α,β-MeATP,0.03 - 3微摩尔)使动脉收缩,但对静脉无作用。α,β-MeATP(3微摩尔)脱敏可阻断ATP诱导的动脉收缩。2-甲硫基ATP(0.1 - 10微摩尔)是一种可作用于P2Y1受体的激动剂,对动脉和静脉均无收缩作用,而UTP是大鼠P2Y2/P2Y4受体激动剂,可使静脉(EC(50) = 15微摩尔)和动脉(EC(50) = 24微摩尔)收缩。UTP诱导的静脉收缩与ATP交叉脱敏,而UTP诱导的动脉收缩不受α,β-MeATP脱敏影响。P2X/P2Y1受体拮抗剂磷酸吡哆醛-6-偶氮苯基-2',4-二磺酸可阻断ATP诱导的动脉收缩(半数抑制浓度[IC(50)] = 4.8微摩尔),但对静脉无作用。苏拉明是一种可阻断P2Y2受体的拮抗剂,可部分抑制ATP和UTP诱导的静脉收缩。免疫组织化学研究显示动脉中有P2X1受体免疫反应性,而静脉中没有。这些数据表明DOCA-盐高血压状态下肠系膜血管对ATP的反应性未改变。ATP分别作用于P2X1和P2Y2受体使肠系膜动脉和静脉收缩,而在动脉中UTP作用于一种未明确的P2受体。